Evidence map›Paper›PMID 38908550›Full record

ArticleJournal of virological methods2024

Product Enhanced Reverse Transcriptase for assessing replication competent virus in vectors retroviral vectors pseudotyped with GALV and VSV-G envelopes.

Kenneth Cornetta, Tsai-Yu Lin, Haipeng Tao, Jianping Huang, Jordon Piskorowski, Parker Wilcox, Danhui Xie, Jing Yao, Kimberley House, Emily Nance and 1 more

Abstract readEvaluation Study
In one paragraph

Article in Journal of virological methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenneth CornettaDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA. Electronic address: kcornett@iu.edu.
Tsai-Yu LinDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Haipeng TaoLillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Jianping HuangLillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Jordon PiskorowskiDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Parker WilcoxDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Danhui XieDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Jing YaoDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Kimberley HouseDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Emily NanceDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.
Lisa DuffyDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, USA.

Funding

PURPOSE OF THE NGVB CONTRACT IS TO CONTINUE SUPPORTING GENE THERAPY RESEARCH.75N92019D00018 · OD · INDIANA UNIVERSITY INDIANAPOLIS · 2019 to 2023
$1.7M
REGULATION OF THE BIOSYNTHESIS OF THE OPIOID PEPTIDES AND OTHER NEUROPEPTIDESZ01HL000018 · NHLBI · HEART, LUNG, AND BLOOD INSTITUTE · PI SABOL, S L · 1985 to 1992
–
Department of Defense W81XWH-20-1-0726NHLBI NIH HHS 75N92019D00018
6 · The paper itself

Abstract

We evaluated the use of the Product Enhanced Reverse Transcriptase (PERT) assay as a means of detecting virus in retroviral vectors products pseudotyped with Gibbon Ape Leukemia Virus (GALV) and Vesicular Stomatitis Virus G (VSVG) envelopes. PERT provides greater standardization than the S+/L- assay which has been used extensively in virus detection. A challenge is that PERT will also detect residual retroviral vectors as vector particles contain reverse transcriptase. Vector products were cultured for 3 weeks on HEK293 cells to amplify any potential virus. In addition, vector supernatant and end-of-production cells were spiked with GALV to evaluate for inhibition by the test article. Results of PERT and the S+/L- assay were compared. PERT and S+/L- assays were both effective in detecting virus. Vector supernatants were negative at the end of 3 weeks of culture by PERT for both GAVL and VSVG pseudotyped vector. In contrast, end-of-production cells were positive by PERT due to persistent vector producing cells. A one-week culture of cell-free media obtained at the 3 weeks timepoint allowed distinction of virus-free test articles from those with virus. The PERT assay is suitable for detecting replication competent retrovirus in vector products pseudotyped with GALV and VSVG envelopes.

Indexed as

Genetic VectorsLeukemia Virus, Gibbon ApeRNA-Directed DNA PolymeraseCell LineHEK293 CellsHumansMembrane GlycoproteinsRetroviridaeViral Envelope ProteinsVirologyVirus ReplicationG protein, vesicular stomatitis virusMembrane GlycoproteinsRNA-Directed DNA PolymeraseViral Envelope ProteinsGene therapyProduct enhanced reverse transcriptase assayReplication competent retrovirusSafety

Identifiers

PMID38908550
PMCPMC11368651

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.